Case Study: Autism Spectrum Disorders - Public awareness and physician detailing will drive market growth

Case Study: Autism Spectrum Disorders - Public awareness and physician detailing will drive market growth


April 15, 2011
33 Pages - SKU: DFMN6329419
License type:
Online Download      US $1,900.00
Global Site License      US $4,750.00
Countries covered: United States

Introduction

To date, only two products have gained approval for the treatment of ASDs; Risperdal (risperidone; Johnson & Johnson) and Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka Pharmaceuticals) are both approved in the US for the treatment of irritability associated with autistic disorder.

Features and benefits
  • Examination of key recommendations contained in published treatment guidelines for the management of ASDs.
  • Overview of the treatment pathway and identification of three key points of influence that may be targeted by pharmaceutical companies.
  • Discussion of key opportunities and treats facing existing and prospective players in the autism spectrum disorders market.
Highlights

ASDs are a complex spectrum of disorders, largely heterogeneous in etiology and symptomatology. Increasing public awareness of the milder symptoms of the disorders would serve to aid earlier recognition and presentation. In addition, increasing physician education in relation to the use of validated screening tools would aid earlier diagnosis.

Given that only two products are approved in the US for one of the behavioural symptoms of ASDs, physicians largely rely on off-label prescribing for the majority of symptoms. With few marketing strategies currently employed, primary care physician detailing has the potential to boost product uptake in the ASDs market.

Targeting the core symptoms of ASDs represents a ‘high-risk, high-reward’ strategy, given the heterogeneity of patient presentation and unknown etiologies, yet high population base. Meanwhile, the traditional route into the ASDs market- targeting of individual symptoms - represents a 'low-risk low-reward' strategy.

Your key questions answered
  • What do current treatment guidelines recommend in relation to pharmacological treatment of ASDs?
  • What is the current typical treatment pathway for patients with ASDs? Where are the key points of influence for market players?
  • Which segment of the ASDs population offers the greatest commercial potential to developers?
  • What actions can pharmaceutical companies take in order to maximize the uptake of products indicated for the treatment of ASDs?
  • Which factors pose the greatest threat to the commercial potential of products indicated for the treatment of ASDs?



More CNS/Neurology reports by Datamonitor

The Depression Market Forecast to 2021 by Datamonitor
The Depression Market Forecast to 2021 Introduction Datamonitor Healthcare values the depression market, comprising of traditional major depressive disorder, as well as treatment-resistant major ...
Treatment Algorithms: Postherpetic Neuralgia by Datamonitor
Prescribing trends reveal that patients with PHN are typically initiated on monotherapy. Since no single therapy provides sufficient efficacy, physicians increasingly turn to combination therapy ...
Market and Product Forecasts: Top 10 Neurology Brands: 2011–21 by Datamonitor
IntroductionThe diverse field of neurology hosts numerous disorders with substantial unmet clinical need, creating a complex but lucrative market. Considerable rewards are available for the ...
Central Nervous System Drug Delivery Specialists by Datamonitor
IntroductionThe blood-brain barrier (BBB) is so effective at limiting the passage of exogenous substances that many drugs with the potential to treat CNS diseases are ...
See all reports like this >>

More United States CNS/Neurology reports

PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022 by GlobalData
PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022SummarySchizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core ...
The 2013-2018 Outlook for Neurodegenerative Drugs in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Neurodegenerative Drugs in the United StatesThis econometric study covers the latent demand outlook for neurodegenerative drugs across the states and cities ...
The 2013-2018 Outlook for Narcolepsy Therapeutics in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Narcolepsy Therapeutics in the United StatesThis econometric study covers the latent demand outlook for narcolepsy therapeutics across the states and cities ...
The 2013-2018 Outlook for Lou Gehrig’s Disease Drugs in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Lou Gehrig’s Disease Drugs in the United StatesThis econometric study covers the latent demand outlook for Lou Gehrig’s disease drugs across ...
See all reports like this >>

More United States reports

The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United StatesThis econometric study covers the latent demand outlook for collagen and (hyaluronic ...
The 2013-2018 Outlook for Relish in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for relish across the states and cities of the United States. Latent demand (in millions of U.S. ...
The 2013-2018 Outlook for Indian Breads in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for Indian breads across the states and cities of the United States. Latent demand (in millions of ...
D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
See all reports like this >>